Zanamivir (Synonyms: 扎那米韦)

目录号: HY-13210 纯度: 99.56%: Data Sheet SDS COA 产品使用指南
FAQs
技术支持

Zanamivir 是流感病毒的神经氨酸酶抑制剂，对于流感病毒 A 和 B 的IC₅₀值分别为 0.95 nM 和 2.7 nM。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Zanamivir Chemical Structure

CAS No. : 139110-80-8

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
5 mg	￥200	In-stock
10 mg	￥320	In-stock
25 mg	￥486	In-stock
50 mg	￥640	In-stock
100 mg	￥950	In-stock
200 mg		询价
500 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Zanamivir:

Zanamivir (hydrate)(5:1) 询价
Zanamivir (Standard) 询价

MCE 顾客使用本产品发表的 14 篇科研文献

Zanamivir 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Antibiotic 亚型特异性产品:

查看所有亚型

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Zanamivir is an influenza viral neuraminidase inhibitor with IC₅₀ values of 0.95 nM and 2.7 nM for influenza A and B, respectively.

IC₅₀ & Target

IC50: 0.95 nM (Influenza A); 2.7 nM (Influenza B)^[1]

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
Fibroblast	CC₅₀	> 200 μM Compound: 2	Cytotoxicity against chicken embryo fibroblasts after 48 hrs by CCK-8 assay Cytotoxicity against chicken embryo fibroblasts after 48 hrs by CCK-8 assay	[PMID: 29965752]
Fibroblast	CC₅₀	> 200 μM Compound: ZA	Cytotoxicity against chicken embryo fibroblasts assessed as reduction in cell viability after 48 hrs by CCK-8 assay Cytotoxicity against chicken embryo fibroblasts assessed as reduction in cell viability after 48 hrs by CCK-8 assay	[PMID: 30365885]
Fibroblast	CC₅₀	> 200 μM Compound: ZAN	Cytotoxicity against chicken embryo fibroblast assessed as reduction in cell viability after 48 hrs by CCK8 assay Cytotoxicity against chicken embryo fibroblast assessed as reduction in cell viability after 48 hrs by CCK8 assay	[PMID: 32092589]
HEK-293T	IC₅₀	1043 μM Compound: 3; GUN	Inhibition of human Neu4 expressed in HEK293T cells using GM3 as substrate incubated for 30 mins by HPLC analysis Inhibition of human Neu4 expressed in HEK293T cells using GM3 as substrate incubated for 30 mins by HPLC analysis	[PMID: 27095056]
HEK-293T	IC₅₀	15.33 μM Compound: 3; GUN	Inhibition of human Neu2 expressed in HEK293T cells using 4MU-Neu5Ac as substrate incubated for 30 mins by HPLC analysis Inhibition of human Neu2 expressed in HEK293T cells using 4MU-Neu5Ac as substrate incubated for 30 mins by HPLC analysis	[PMID: 27095056]
HEK-293T	IC₅₀	392 μM Compound: 3; GUN	Inhibition of human Neu4 expressed in HEK293T cells using 4MU-Neu5Ac as substrate incubated for 30 mins by HPLC analysis Inhibition of human Neu4 expressed in HEK293T cells using 4MU-Neu5Ac as substrate incubated for 30 mins by HPLC analysis	[PMID: 27095056]
HEK-293T	IC₅₀	8.17 μM Compound: 3; GUN	Inhibition of human Neu3 expressed in HEK293T cells using GM3 as substrate incubated for 30 mins by HPLC analysis Inhibition of human Neu3 expressed in HEK293T cells using GM3 as substrate incubated for 30 mins by HPLC analysis	[PMID: 27095056]
HEK-293T	IC₅₀	> 1000 μM Compound: 3; GUN	Inhibition of human Neu1 expressed in HEK293T cells using 4MU-Neu5Ac as substrate incubated for 30 mins by HPLC analysis Inhibition of human Neu1 expressed in HEK293T cells using 4MU-Neu5Ac as substrate incubated for 30 mins by HPLC analysis	[PMID: 27095056]
HEK-293T	IC₅₀	> 500 μM Compound: 6	Inhibition of human CathA-IRES-6His-tagged NEU1 expressed in HEK293T cells using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by fluorescence based assay Inhibition of human CathA-IRES-6His-tagged NEU1 expressed in HEK293T cells using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by fluorescence based assay	[PMID: 29425031]
HEK293	IC₅₀	0.6 nM Compound: 1	Inhibition of oseltamivir-resistant Influenza A virus A/WSN/1933(H1N1) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay Inhibition of oseltamivir-resistant Influenza A virus A/WSN/1933(H1N1) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay	[PMID: 27167096]
HEK293	IC₅₀	0.7 nM Compound: 1	Inhibition of oseltamivir-resistant Influenza A virus A/Vietnam/1194/2004(H5N1) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay Inhibition of oseltamivir-resistant Influenza A virus A/Vietnam/1194/2004(H5N1) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay	[PMID: 27167096]
HEK293	IC₅₀	1.7 nM Compound: 1	Inhibition of oseltamivir-resistant Influenza A virus A/Vietnam/1194/2004(H5N1) recombinant neuraminidase H275Y mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay Inhibition of oseltamivir-resistant Influenza A virus A/Vietnam/1194/2004(H5N1) recombinant neuraminidase H275Y mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay	[PMID: 27167096]
HEK293	IC₅₀	1.9 nM Compound: 1	Inhibition of Influenza A virus A/WSN/1933(H1N1) recombinant neuraminidase H275Y mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay Inhibition of Influenza A virus A/WSN/1933(H1N1) recombinant neuraminidase H275Y mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay	[PMID: 27167096]
HEK293	IC₅₀	16.4 μM Compound: zanamivir	Inhibition of human NEU2 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using 4MU-NeuAc substrate Inhibition of human NEU2 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using 4MU-NeuAc substrate	[PMID: 18694948]
HEK293	IC₅₀	2713 μM Compound: zanamivir	Inhibition of human NEU1 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using 4MU-NeuAc substrate Inhibition of human NEU1 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using 4MU-NeuAc substrate	[PMID: 18694948]
HEK293	IC₅₀	4.2 nM Compound: 1	Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay	[PMID: 27167096]
HEK293	IC₅₀	45 nM Compound: 1	Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant neuraminidase R292K mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant neuraminidase R292K mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay	[PMID: 27167096]
HEK293	IC₅₀	487 μM Compound: zanamivir	Inhibition of human NEU4 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using 4MU-NeuAc substrate Inhibition of human NEU4 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using 4MU-NeuAc substrate	[PMID: 18694948]
HEK293	IC₅₀	6 nM Compound: 1	Inhibition of Influenza A virus A/Shanghai/01/2014(H7N9) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay Inhibition of Influenza A virus A/Shanghai/01/2014(H7N9) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay	[PMID: 27167096]
HEK293	IC₅₀	6.8 μM Compound: zanamivir	Inhibition of human NEU3 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using ganglioside GM3 substrate Inhibition of human NEU3 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using ganglioside GM3 substrate	[PMID: 18694948]
HEK293	IC₅₀	690 μM Compound: zanamivir	Inhibition of human NEU4 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using ganglioside GM3 substrate Inhibition of human NEU4 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using ganglioside GM3 substrate	[PMID: 18694948]
HEK293	IC₅₀	> 83000 nM Compound: 1	Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant neuraminidase E119A mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant neuraminidase E119A mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay	[PMID: 27167096]
MDCK	CC₅₀	176.4 nM Compound: Relenza	Cytotoxicity against MDCK cells by SRB assay Cytotoxicity against MDCK cells by SRB assay	[PMID: 26077494]
MDCK	CC₅₀	> 100 μM Compound: 1; ZA	Cytotoxicity against MDCK cells after 48 hrs by CellTiter96 aqueous non-radioactive cell proliferation assay Cytotoxicity against MDCK cells after 48 hrs by CellTiter96 aqueous non-radioactive cell proliferation assay	[PMID: 29843102]
MDCK	CC₅₀	> 100 μM Compound: 45	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay	[PMID: 30389293]
MDCK	CC₅₀	> 100 μM Compound: Zanamivir	Cytotoxicity against dog MDCK cells assessed as cell viability by MTS assay Cytotoxicity against dog MDCK cells assessed as cell viability by MTS assay	[PMID: 23117173]
MDCK	CC₅₀	> 100 μM Compound: Zanamivir	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 24974341]
MDCK	CC₅₀	> 100 μM Compound: Zanamivir	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 5 to 6 days by MTS assay Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 5 to 6 days by MTS assay	[PMID: 28477572]
MDCK	CC₅₀	> 100 μM Compound: Zanamivir	Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 3 to 6 days by MTS assay Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 3 to 6 days by MTS assay	[PMID: 29886325]
MDCK	CC₅₀	> 100 μM Compound: Zanamivir	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by MTS assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by MTS assay	[PMID: 30170320]
MDCK	CC₅₀	> 100 μM Compound: Zanamivir	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 35212527]
MDCK	CC₅₀	> 100 μM Compound: Zanamivir	Cytotoxicity against dog MDCK cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay Cytotoxicity against dog MDCK cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay	[PMID: 37252100]
MDCK	CC₅₀	> 100 μM Compound: Zanamivir	Cytotoxicity against MDCK cells by CCK-8 assay Cytotoxicity against MDCK cells by CCK-8 assay	[PMID: 37531746]
MDCK	CC₅₀	> 100.03 μM Compound: Zanamivir	Cytotoxicity against MDCK cells after 72 hrs by MTT assay Cytotoxicity against MDCK cells after 72 hrs by MTT assay	[PMID: 24803363]
MDCK	CC₅₀	> 100.32 μM Compound: zanamivir	Cytotoxicity against MDCK cells by MTT assay Cytotoxicity against MDCK cells by MTT assay	[PMID: 22226654]
MDCK	CC₅₀	> 1 x 10⁵ nM Compound: 1	Cytotoxicity against MDCK cells after 48 hrs by CellTiter 96 AQueous Non-Radioactive cell proliferation assay Cytotoxicity against MDCK cells after 48 hrs by CellTiter 96 AQueous Non-Radioactive cell proliferation assay	[PMID: 27167096]
MDCK	CC₅₀	> 250 μM Compound: 2	Cytotoxicity against MDCK cells after 48 hrs by MTT assay Cytotoxicity against MDCK cells after 48 hrs by MTT assay	[PMID: 29965752]
MDCK	CC₅₀	> 250 μM Compound: ZA	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30365885]
MDCK	CC₅₀	> 250 μM Compound: ZA	Cytotoxicity against MDCK cells assessed as reduction in cell viability by MTT assay Cytotoxicity against MDCK cells assessed as reduction in cell viability by MTT assay	[PMID: 33385836]
MDCK	CC₅₀	> 3612 μM Compound: zanamivir	Cytotoxicity against MDCK cells Cytotoxicity against MDCK cells	[PMID: 17194832]
MDCK	CC₅₀	>= 100 μM Compound: Zanamivir	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 3 days by coulter counter method Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 3 days by coulter counter method	[PMID: 31586832]
MDCK	EC₅₀	0.012 μM Compound: zanamivir	Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay	[PMID: 17194832]
MDCK	EC₅₀	0.013 μM Compound: 3	Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity	[PMID: 20452227]
MDCK	EC₅₀	0.04 μM Compound: 1 (GG167)	Inhibitory activity against Influenza virus in MDCK cells Inhibitory activity against Influenza virus in MDCK cells	10.1016/0960-894X(95)00390-F
MDCK	EC₅₀	0.063 μM Compound: Zanamivir	Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay	[PMID: 23117173]
MDCK	EC₅₀	0.072 μM Compound: Zanamivir	Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis	[PMID: 23117173]
MDCK	EC₅₀	0.09 μM Compound: zanamivir	Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay	[PMID: 17194832]
MDCK	EC₅₀	0.15 μM Compound: zanamivir	Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by neutral red uptake assay Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by neutral red uptake assay	[PMID: 17194832]
MDCK	EC₅₀	0.15 μM Compound: zanamivir	Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by neutral red uptake assay Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by neutral red uptake assay	[PMID: 17194832]
MDCK	EC₅₀	0.16 μM Compound: zanamivir	Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	0.3 μM Compound: Zanamivir	Antiviral activity against Influenza A/PR/8/34 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay Antiviral activity against Influenza A/PR/8/34 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay	[PMID: 23149298]
MDCK	EC₅₀	0.44 μM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis	[PMID: 23117173]
MDCK	EC₅₀	0.47 μM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy	[PMID: 24974341]
MDCK	EC₅₀	0.48 μM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay	[PMID: 23117173]
MDCK	EC₅₀	0.5 μM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay	[PMID: 24974341]
MDCK	EC₅₀	1.2 μM Compound: zanamivir	Antiviral activity against Influenza A virus (A/HK/7/87 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against Influenza A virus (A/HK/7/87 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	1.22 μM Compound: 2	Antiviral activity against Oseltamivir-resistant Influenza A virus A/Berlin/55/08(H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs Antiviral activity against Oseltamivir-resistant Influenza A virus A/Berlin/55/08(H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs	[PMID: 24422530]
MDCK	EC₅₀	1.6 μM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 23099097]
MDCK	EC₅₀	1.7 μM Compound: zanamivir	Antiviral activity against amantadine-sensitive Influenza A virus (A/Ned/378/05 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against amantadine-sensitive Influenza A virus (A/Ned/378/05 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	1.8 μM Compound: Zanamivir	Antiviral activity against Influenza A/HK/7/87 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay Antiviral activity against Influenza A/HK/7/87 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay	[PMID: 23149298]
MDCK	EC₅₀	11 nM Compound: 1	Antiviral activity against influenza A virus A/WSN/1933 H1N1 infected in MDCK cells after 3 days by plaque reduction assay Antiviral activity against influenza A virus A/WSN/1933 H1N1 infected in MDCK cells after 3 days by plaque reduction assay	[PMID: 19522501]
MDCK	EC₅₀	12 μM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis	[PMID: 23117173]
MDCK	EC₅₀	12 μM Compound: Zanamivir	Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy	[PMID: 24974341]
MDCK	EC₅₀	149 nM Compound: Zanamivir, Relenza	Antiviral activity against Influenza B virus (B/Harbin/07/94) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by MTT assay Antiviral activity against Influenza B virus (B/Harbin/07/94) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by MTT assay	10.1039/C2MD20300F
MDCK	EC₅₀	16.3 nM Compound: 1	Antiviral activity against oseltamivir-resistant Influenza A virus A/WSN/1933(H1N1) infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by CellTiter 96 AQueous Non-Radioactive cell proliferation assay Antiviral activity against oseltamivir-resistant Influenza A virus A/WSN/1933(H1N1) infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by CellTiter 96 AQueous Non-Radioactive cell proliferation assay	[PMID: 27167096]
MDCK	EC₅₀	2.8 μM Compound: Zanamivir, 1	Antiviral activity against avian influenza virus H5N1 in MDCK cells measured as reduction in infected cells relative to control Antiviral activity against avian influenza virus H5N1 in MDCK cells measured as reduction in infected cells relative to control	[PMID: 16876409]
MDCK	EC₅₀	20 μM Compound: Zanamivir	Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay	[PMID: 24974341]
MDCK	EC₅₀	23 μM Compound: Zanamivir	Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 23099097]
MDCK	EC₅₀	3.5 nM Compound: ZA	Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in MDCK cells assessed as inhibition of virus induced cytopathic effect Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in MDCK cells assessed as inhibition of virus induced cytopathic effect	[PMID: 22963087]
MDCK	EC₅₀	34 nM Compound: 1a, ZA	Antiviral activity against influenza A virus A/WSN/1933 (H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs Antiviral activity against influenza A virus A/WSN/1933 (H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs	[PMID: 21778065]
MDCK	EC₅₀	34 μM Compound: Zanamivir	Antiviral activity against Influenza B/HK/5/72 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay Antiviral activity against Influenza B/HK/5/72 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay	[PMID: 23149298]
MDCK	EC₅₀	4.8 μM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 23099097]
MDCK	EC₅₀	45 μM Compound: Zanamivir	Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy	[PMID: 24974341]
MDCK	EC₅₀	5 μM Compound: zanamivir	Antiviral activity against amantadine-sensitive Influenza A virus (A/FM/1/47 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against amantadine-sensitive Influenza A virus (A/FM/1/47 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	53 μM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay	[PMID: 23117173]
MDCK	EC₅₀	6 μM Compound: zanamivir	Antiviral activity against amantadine-resistant Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against amantadine-resistant Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	6.56 μM Compound: 2	Antiviral activity against Influenza A virus A/Jena/5258/2009(H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs Antiviral activity against Influenza A virus A/Jena/5258/2009(H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs	[PMID: 24422530]
MDCK	EC₅₀	613 nM Compound: 1	Antiviral activity against influenza A virus A/Vietnam/1194/2004 H5N1 infected in MDCK cells after 3 days by plaque reduction assay Antiviral activity against influenza A virus A/Vietnam/1194/2004 H5N1 infected in MDCK cells after 3 days by plaque reduction assay	[PMID: 19522501]
MDCK	EC₅₀	786 nM Compound: Zanamivir, Relenza	Antiviral activity against Influenza A virus (A/Sydney/5/1997(H3N2)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by MTT assay Antiviral activity against Influenza A virus (A/Sydney/5/1997(H3N2)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by MTT assay	10.1039/C2MD20300F
MDCK	EC₅₀	8.7 μM Compound: zanamivir	Antiviral activity against Influenza A virus (A/Ishikawa/7/82 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against Influenza A virus (A/Ishikawa/7/82 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	8.9 μM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy	[PMID: 24974341]
MDCK	EC₅₀	9 μM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay	[PMID: 24974341]
MDCK	EC₅₀	9.4 μM Compound: Zanamivir	Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay	[PMID: 24974341]
MDCK	IC₅₀	0.001 μM Compound: Zanamivir	Antiviral activity against Influenza A virus A/Hong Kong/8/1968 (H3N2) infected in MDCK cells assessed as reduction in virus plaque formation after 5 days Antiviral activity against Influenza A virus A/Hong Kong/8/1968 (H3N2) infected in MDCK cells assessed as reduction in virus plaque formation after 5 days	[PMID: 24374271]
MDCK	IC₅₀	0.01 μM Compound: Zanamivir	Antiviral activity against Influenza A virus A/California/07/2009 (H1N1) infected in MDCK cells assessed as reduction in virus plaque formation after 5 days Antiviral activity against Influenza A virus A/California/07/2009 (H1N1) infected in MDCK cells assessed as reduction in virus plaque formation after 5 days	[PMID: 24374271]
MDCK	IC₅₀	0.02 μM Compound: 4	Antiviral activity against human influenza B virus B/TW/70325/05 in MDCK cells assessed as reduction of virus-induced cytopathic Antiviral activity against human influenza B virus B/TW/70325/05 in MDCK cells assessed as reduction of virus-induced cytopathic	[PMID: 20092255]
MDCK	IC₅₀	0.03 μM Compound: 4	Antiviral activity against human influenza A virus A/TW/3446/04 (H3N2) in MDCK cells assessed as reduction of virus-induced cytopathic effect Antiviral activity against human influenza A virus A/TW/3446/04 (H3N2) in MDCK cells assessed as reduction of virus-induced cytopathic effect	[PMID: 20092255]
MDCK	IC₅₀	0.03 μM Compound: 4	Antiviral activity against human influenza B virus B/TW/710/05 in MDCK cells assessed as reduction of virus-induced cytopathic Antiviral activity against human influenza B virus B/TW/710/05 in MDCK cells assessed as reduction of virus-induced cytopathic	[PMID: 20092255]
MDCK	IC₅₀	0.06 μM Compound: 4	Antiviral activity against human influenza A virus A/WSN/33 (H1N1) in MDCK cells assessed as reduction of virus-induced cytopathic effect Antiviral activity against human influenza A virus A/WSN/33 (H1N1) in MDCK cells assessed as reduction of virus-induced cytopathic effect	[PMID: 20092255]
MDCK	IC₅₀	0.075 μM Compound: zanamivir	Antiviral activity against influenza A/Yuefang/243/72 (H3N2) virus in MDCK cells by CPE assay Antiviral activity against influenza A/Yuefang/243/72 (H3N2) virus in MDCK cells by CPE assay	[PMID: 17611105]
MDCK	IC₅₀	0.1 μM Compound: 4	Antiviral activity against human influenza B virus B/TW/99/07 in MDCK cells assessed as reduction of virus-induced cytopathic Antiviral activity against human influenza B virus B/TW/99/07 in MDCK cells assessed as reduction of virus-induced cytopathic	[PMID: 20092255]
MDCK	IC₅₀	0.12 μM Compound: zanamivir	Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells assessed as inhibition of viral replication by plaque reduction assay Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells assessed as inhibition of viral replication by plaque reduction assay	[PMID: 22226654]
MDCK	IC₅₀	0.2 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.2 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 1 nM of compound after 1 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 1 nM of compound after 1 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.2 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 25 nM of zanamivir after 3 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 25 nM of zanamivir after 3 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.2 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 3,125 nM of zanamivir after 6 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 3,125 nM of zanamivir after 6 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.2 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 5 nM of zanamivir after 2 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 5 nM of zanamivir after 2 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.2 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 625 nM of zanamivir after 5 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 625 nM of zanamivir after 5 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.2 μM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells selected at 16 uM of zanamivir after 7 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells selected at 16 uM of zanamivir after 7 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M mutant infected in MDCK cells selected at 3,125 nM of oseltamivir after 6 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M mutant infected in MDCK cells selected at 3,125 nM of oseltamivir after 6 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 1 nM of oseltamivir after 1 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 1 nM of oseltamivir after 1 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 125 nM of oseltamivir after 4 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 125 nM of oseltamivir after 4 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 125 nM of zanamivir after 4 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 125 nM of zanamivir after 4 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 25 nM of oseltamivir after 3 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 25 nM of oseltamivir after 3 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 5 nM of oseltamivir after 2 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 5 nM of oseltamivir after 2 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 625 nM of oseltamivir after 5 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 625 nM of oseltamivir after 5 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 25 nM of oseltamivir after 3 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 25 nM of oseltamivir after 3 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 50 nM of oseltamivir after 4 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 50 nM of oseltamivir after 4 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.3 μM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K234Q mutant gene and neuraminidase I222M mutant infected in MDCK cells selected at 16 uM of oseltamivir after 7 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K234Q mutant gene and neuraminidase I222M mutant infected in MDCK cells selected at 16 uM of oseltamivir after 7 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.35 μM Compound: 4	Antiviral activity against human influenza A virus A/TW/141/04 (H1N1) in MDCK cells assessed as reduction of virus-induced cytopathic effect Antiviral activity against human influenza A virus A/TW/141/04 (H1N1) in MDCK cells assessed as reduction of virus-induced cytopathic effect	[PMID: 20092255]
MDCK	IC₅₀	0.385 μM Compound: zanamivir	Antiviral activity against influenza A/Hanfang/359/95 (H3N2) virus in MDCK cells by CPE assay Antiviral activity against influenza A/Hanfang/359/95 (H3N2) virus in MDCK cells by CPE assay	[PMID: 17611105]
MDCK	IC₅₀	0.4 nM Compound: Zanamivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase	[PMID: 19651908]
MDCK	IC₅₀	0.4 μM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K234Q mutant gene and neuraminidase I222M and H274Y mutant infected in MDCK cells selected at 78 uM of oseltamivir after 8 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K234Q mutant gene and neuraminidase I222M and H274Y mutant infected in MDCK cells selected at 78 uM of oseltamivir after 8 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.469 μM Compound: zanamivir	Antiviral activity against influenza A/Jifang/15/90 (H3N2) virus in MDCK cells by CPE assay Antiviral activity against influenza A/Jifang/15/90 (H3N2) virus in MDCK cells by CPE assay	[PMID: 17611105]
MDCK	IC₅₀	0.5 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	0.5 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	0.5 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells selected at 1250 nM of oseltamivir after 6 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells selected at 1250 nM of oseltamivir after 6 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.5 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells selected at 6250 nM of oseltamivir after 7 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells selected at 6250 nM of oseltamivir after 7 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.5 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.5 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 250 nM of oseltamivir after 5 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 250 nM of oseltamivir after 5 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.5 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 5 nM of oseltamivir after 2 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 5 nM of oseltamivir after 2 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.5 nM Compound: Zanamivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase	[PMID: 19651908]
MDCK	IC₅₀	0.5 μM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K234Q mutant gene and neuraminidase I222M and H274Y mutant infected in MDCK cells selected at 390 uM of oseltamivir after 9 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K234Q mutant gene and neuraminidase I222M and H274Y mutant infected in MDCK cells selected at 390 uM of oseltamivir after 9 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.5 μM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin A45S, K156E, P210Q, L313F mutant gene and neuraminidase H274Y mutant infected in MDCK cells selected at 31 uM of oseltamivir after 9 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin A45S, K156E, P210Q, L313F mutant gene and neuraminidase H274Y mutant infected in MDCK cells selected at 31 uM of oseltamivir after 9 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.5 μM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin A45S, K156E, P210Q, L313F mutant gene and neuraminidase H274Y mutant infected in MDCK cells selected at 781 uM of oseltamivir after 10 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin A45S, K156E, P210Q, L313F mutant gene and neuraminidase H274Y mutant infected in MDCK cells selected at 781 uM of oseltamivir after 10 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.5 μM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells selected at 31 uM of oseltamivir after 8 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells selected at 31 uM of oseltamivir after 8 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.6 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	0.6 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G mutant infected in MDCK cells selected at 1250 nM of compound after 6 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G mutant infected in MDCK cells selected at 1250 nM of compound after 6 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.6 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase	[PMID: 19651908]
MDCK	IC₅₀	0.6 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 25 nM of zanamivir after 3 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 25 nM of zanamivir after 3 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.6 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 250 nM of zanamivir after 5 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 250 nM of zanamivir after 5 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.6 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 5 nM of zanamivir after 2 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 5 nM of zanamivir after 2 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.7 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	0.7 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 1 nM of oseltamivir after 1 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 1 nM of oseltamivir after 1 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.7 nM Compound: Zanamivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase	[PMID: 19651908]
MDCK	IC₅₀	0.7 μM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K234Q mutant gene and neuraminidase I222M and H274Y mutant infected in MDCK cells selected at 1950 uM of oseltamivir after 10 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K234Q mutant gene and neuraminidase I222M and H274Y mutant infected in MDCK cells selected at 1950 uM of oseltamivir after 10 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.76 nM Compound: zanamivir	Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by NA inhibition assay Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	0.8 nM Compound: 2	Competitive inhibition of MDCK infected Influenza A virus A/WSN/33(H1N1) neuraminidase using MU-NANA as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by spectrofluorometric method Competitive inhibition of MDCK infected Influenza A virus A/WSN/33(H1N1) neuraminidase using MU-NANA as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by spectrofluorometric method	[PMID: 27487569]
MDCK	IC₅₀	0.8 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 50 nM of zanamivir after 4 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 50 nM of zanamivir after 4 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.8 nM Compound: Zanamivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase	[PMID: 19651908]
MDCK	IC₅₀	0.88 μM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells assessed as inhibition of viral replication after 2 to 3 days by crystal violet staining-based plaque reduction assay Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells assessed as inhibition of viral replication after 2 to 3 days by crystal violet staining-based plaque reduction assay	[PMID: 24803363]
MDCK	IC₅₀	1 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase	[PMID: 19651908]
MDCK	IC₅₀	1.09 nM Compound: zanamivir	Antiviral activity against sInfluenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD2 additional passages in MDCK cells by NA inhibition assay Antiviral activity against sInfluenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD2 additional passages in MDCK cells by NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	1.1 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	1.1 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 1 nM of zanamivir after 1 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 1 nM of zanamivir after 1 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	1.2 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G mutant infected in MDCK cells selected at 6250 nM of compound after 7 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G mutant infected in MDCK cells selected at 6250 nM of compound after 7 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	1.3 nM Compound: Zanamivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase	[PMID: 19651908]
MDCK	IC₅₀	1.38 nM Compound: zanamivir	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	1.4 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	1.5 nM Compound: Zanamivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase	[PMID: 19651908]
MDCK	IC₅₀	1.54 nM Compound: zanamivir	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by NA inhibition assay Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	1.6 nM Compound: zanamivir	Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by fluorescent NA inhibition assay Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by fluorescent NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	10.86 nM Compound: 3; GUN	Antiviral activity against Influenza A virus (A/duck/Shiga/8/2004(H4N6)) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay Antiviral activity against Influenza A virus (A/duck/Shiga/8/2004(H4N6)) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay	[PMID: 27095056]
MDCK	IC₅₀	11.95 nM Compound: 3; GUN	Antiviral activity against Influenza A virus (A/duck/Tsukuba/394/2005(H5N3)) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay Antiviral activity against Influenza A virus (A/duck/Tsukuba/394/2005(H5N3)) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay	[PMID: 27095056]
MDCK	IC₅₀	12.67 nM Compound: zanamivir	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	15.58 nM Compound: 3; GUN	Antiviral activity against Influenza A virus (A/mallard/Hokkaido/24/2009(H5N1)) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay Antiviral activity against Influenza A virus (A/mallard/Hokkaido/24/2009(H5N1)) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay	[PMID: 27095056]
MDCK	IC₅₀	1579 μM Compound: zanamivir	Antiviral activity against influenza B/Sichuan/83/2000 virus in MDCK cells by CPE assay Antiviral activity against influenza B/Sichuan/83/2000 virus in MDCK cells by CPE assay	[PMID: 17611105]
MDCK	IC₅₀	16.7 μM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K205EQ mutant gene and neuraminidase E119G mutant infected in MDCK cells selected at 1950 uM of zanamivir after 10 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K205EQ mutant gene and neuraminidase E119G mutant infected in MDCK cells selected at 1950 uM of zanamivir after 10 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	16.7 μM Compound: zanamivir	Antiviral activity against influenza A/Jingfang/262/95(H1N1) virus in MDCK cells by CPE assay Antiviral activity against influenza A/Jingfang/262/95(H1N1) virus in MDCK cells by CPE assay	[PMID: 17611105]
MDCK	IC₅₀	16.72 nM Compound: 3; GUN	Antiviral activity against Influenza A virus (A/duck/Tsukuba/28/2006(H3N8)) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay Antiviral activity against Influenza A virus (A/duck/Tsukuba/28/2006(H3N8)) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay	[PMID: 27095056]
MDCK	IC₅₀	18.59 nM Compound: zanamivir	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	19.1 μM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K205EQ mutant gene and neuraminidase E119G mutant infected in MDCK cells selected at 390 uM of zanamivir after 9 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K205EQ mutant gene and neuraminidase E119G mutant infected in MDCK cells selected at 390 uM of zanamivir after 9 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	2.73 nM Compound: 3; GUN	Antiviral activity against Influenza A virus (A/duck/Tsukuba/67/2005(H1N1)) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay Antiviral activity against Influenza A virus (A/duck/Tsukuba/67/2005(H1N1)) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay	[PMID: 27095056]
MDCK	IC₅₀	223 μM Compound: zanamivir	Antiviral activity against influenza B/Jingfang/76/98 in MDCK cells by CPE assay Antiviral activity against influenza B/Jingfang/76/98 in MDCK cells by CPE assay	[PMID: 17611105]
MDCK	IC₅₀	25.5 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase D198G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase D198G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase	[PMID: 19651908]
MDCK	IC₅₀	28.4 ng/mL Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by crystal violet staining method Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by crystal violet staining method	[PMID: 23411074]
MDCK	IC₅₀	28.83 nM Compound: 3; GUN	Antiviral activity against Influenza A virus A/duck/Chiba/13/06(H12N5) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay Antiviral activity against Influenza A virus A/duck/Chiba/13/06(H12N5) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay	[PMID: 27095056]
MDCK	IC₅₀	3.8 nM Compound: zanamivir	Antiviral activity against sInfluenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by fluorescent NA inhibition assay Antiviral activity against sInfluenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by fluorescent NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	4 μM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells selected at 78 uM of zanamivir after 8 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells selected at 78 uM of zanamivir after 8 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	40.3 μM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G mutant infected in MDCK cells selected at 781 uM of zanamivir after 10 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G mutant infected in MDCK cells selected at 781 uM of zanamivir after 10 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	5.49 nM Compound: zanamivir	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	5015 μM Compound: zanamivir	Antiviral activity against influenza B/Jifang/13/97 virus in MDCK cells by CPE assay Antiviral activity against influenza B/Jifang/13/97 virus in MDCK cells by CPE assay	[PMID: 17611105]
MDCK	IC₅₀	58.37 nM Compound: 3; GUN	Antiviral activity against Influenza A virus (A/duck/Tsukuba/700/2007(H7N7)) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay Antiviral activity against Influenza A virus (A/duck/Tsukuba/700/2007(H7N7)) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay	[PMID: 27095056]
MDCK	IC₅₀	6.5 nM Compound: 3; GUN	Antiviral activity against Influenza A virus (A/duck/Tsukuba/28/2005(H6N2)) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay Antiviral activity against Influenza A virus (A/duck/Tsukuba/28/2005(H6N2)) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay	[PMID: 27095056]
MDCK	IC₅₀	6.6 ng/mL Compound: Zanamivir	Inhibitory concentration against Influenza A virus (A/Yamagata/32/89) MDCK cells determined by plaque reduction assay Inhibitory concentration against Influenza A virus (A/Yamagata/32/89) MDCK cells determined by plaque reduction assay	[PMID: 12639555]
MDCK	IC₅₀	64.7 nM Compound: Relenza	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by SRB assay Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by SRB assay	[PMID: 26077494]
MDCK	IC₅₀	65 nM Compound: 3; GUN	Antiviral activity against Influenza A virus A/duck/Tsukuba/441/05(H11N9) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay Antiviral activity against Influenza A virus A/duck/Tsukuba/441/05(H11N9) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay	[PMID: 27095056]
MDCK	IC₅₀	677.3 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	7 μM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G mutant infected in MDCK cells selected at 31 uM of compound after 8 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G mutant infected in MDCK cells selected at 31 uM of compound after 8 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	7.8 μM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G and E119G mutant infected in MDCK cells selected at 31 uM of zanamivir after 9 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G and E119G mutant infected in MDCK cells selected at 31 uM of zanamivir after 9 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	868.1 nM Compound: Zanamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase	[PMID: 19651908]
MDCK	IC₅₀	9.33 nM Compound: 3; GUN	Antiviral activity against Influenza A virus (A/duck/Tsukuba/20/2007(H8N4)) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay Antiviral activity against Influenza A virus (A/duck/Tsukuba/20/2007(H8N4)) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay	[PMID: 27095056]
Vero	EC₅₀	0.015 mM Compound: Zanamivir	Antiviral activity against unidentified influenza virus (H5N1) infected African green monkey Vero cells assessed as protection against virus-induced cytopathic effect incubated for 3 days measured on day 4 post infection by MTT assay Antiviral activity against unidentified influenza virus (H5N1) infected African green monkey Vero cells assessed as protection against virus-induced cytopathic effect incubated for 3 days measured on day 4 post infection by MTT assay	10.1007/s00044-012-0205-9

体外研究
(In Vitro)

Zanamivir 与神经氨酸酶活性位点的一组氨基酸相互作用，这些氨基酸在所有甲型和乙型流感病毒株中都是保守的。Zanamivir 阻断神经氨酸酶的作用，阻止唾液酸在细胞受体上的裂解，从而阻止新形成的病毒体的释放和扩散^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Zanamivir 口服生物利用度较低，仅为 4-17%。Zanamivir 的强亲水性限制了其在肠道上皮的转运，因此口服给药一直存在问题。胆酸钠、羟丙基 β-环糊精等渗透促进剂可与 Zanamivir 合用，以增强肠道通透性^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

332.31

Formula

C₁₂H₂₀N₄O₇

CAS 号

139110-80-8

性状

固体

颜色

White to off-white

中文名称

扎那米韦

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性数据

细胞实验：

H₂O 中的溶解度 : ≥ 33.33 mg/mL (100.30 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.0092 mL	15.0462 mL	30.0924 mL
5 mM	0.6018 mL	3.0092 mL	6.0185 mL
10 mM	0.3009 mL	1.5046 mL	3.0092 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： PBS
Solubility: 9.09 mg/mL (27.35 mM); 澄清溶液; 超声助溶 (<60°C)

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

计算结果

工作液所需浓度 : mg/mL

该产品水溶性佳，请具体参考实测水 / PBS / Saline 中的溶解度数据。

您所需的储备液浓度超过该产品的实测溶解度，如有需要，请与 MCE 中国技术支持联系。

纯度 & 产品资料

纯度: 99.92%

选择批次：

Data Sheet (642 KB) SDS (393 KB)

COA (293 KB) RP-HPLC (308 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Gubareva LV, et al. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates ofinfluenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother. 2001 Dec;45(12):3403-8. [Content Brief]

[2]. McKimm-Breschkin JL, et al. Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance. Treat Respir Med. 2005;4(2):107-16. [Content Brief]

[3]. Shanmugam S, et al. Zanamivir oral delivery: enhanced plasma and lung bioavailability in rats. Biomol Ther (Seoul). 2013 Mar;21(2):161-9. [Content Brief]

Animal Administration ^[3]	Rats: Formulations PO-SC (Zanamivir with SC for p.o.) and PO-C (Zanamivir control solution for p.o.) are administered orally at a Zanamivir dose of 10 mg/kg, and IV-R (reference Zanamivir saline solution for i.v.) is administered i.v. at a dose of 1 mg/kg to rats under conscious condition. Blood samples are collected prior to and at 0.5, 1, 2, 3, 4, 6, 8, and 24 hr after administration. At each sampling point, three rats from each group are sacrificed after blood collection to extract the lungs. The lungs are cleansed with saline after extraction of lungs from the rats through a chest incision. The lungs are then transferred into E-tube and stored in the freezer (-80°C) until analysis. Plasma samples are harvested by centrifugation at 1,500 × g for 10 min and stored at -20°C until analysis. The analysis of Zanamivir in both plasma and lungs is performed using before-mentioned LC-MS/MS method^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Gubareva LV, et al. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates ofinfluenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother. 2001 Dec;45(12):3403-8. [Content Brief] [2]. McKimm-Breschkin JL, et al. Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance. Treat Respir Med. 2005;4(2):107-16. [Content Brief] [3]. Shanmugam S, et al. Zanamivir oral delivery: enhanced plasma and lung bioavailability in rats. Biomol Ther (Seoul). 2013 Mar;21(2):161-9. [Content Brief]

Animal Administration
^[3]

Rats: Formulations PO-SC (Zanamivir with SC for p.o.) and PO-C (Zanamivir control solution for p.o.) are administered orally at a Zanamivir dose of 10 mg/kg, and IV-R (reference Zanamivir saline solution for i.v.) is administered i.v. at a dose of 1 mg/kg to rats under conscious condition. Blood samples are collected prior to and at 0.5, 1, 2, 3, 4, 6, 8, and 24 hr after administration. At each sampling point, three rats from each group are sacrificed after blood collection to extract the lungs. The lungs are cleansed with saline after extraction of lungs from the rats through a chest incision. The lungs are then transferred into E-tube and stored in the freezer (-80°C) until analysis. Plasma samples are harvested by centrifugation at 1,500 × g for 10 min and stored at -20°C until analysis. The analysis of Zanamivir in both plasma and lungs is performed using before-mentioned LC-MS/MS method^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

[1]. Gubareva LV, et al. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates ofinfluenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother. 2001 Dec;45(12):3403-8. [Content Brief]

[2]. McKimm-Breschkin JL, et al. Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance. Treat Respir Med. 2005;4(2):107-16. [Content Brief]

[3]. Shanmugam S, et al. Zanamivir oral delivery: enhanced plasma and lung bioavailability in rats. Biomol Ther (Seoul). 2013 Mar;21(2):161-9. [Content Brief]

Zanamivir 相关分类

Infection

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

H₂O	1 mM	3.0092 mL	15.0462 mL	30.0924 mL	75.2310 mL
	5 mM	0.6018 mL	3.0092 mL	6.0185 mL	15.0462 mL
	10 mM	0.3009 mL	1.5046 mL	3.0092 mL	7.5231 mL
	15 mM	0.2006 mL	1.0031 mL	2.0062 mL	5.0154 mL
	20 mM	0.1505 mL	0.7523 mL	1.5046 mL	3.7615 mL
	25 mM	0.1204 mL	0.6018 mL	1.2037 mL	3.0092 mL
	30 mM	0.1003 mL	0.5015 mL	1.0031 mL	2.5077 mL
	40 mM	0.0752 mL	0.3762 mL	0.7523 mL	1.8808 mL
	50 mM	0.0602 mL	0.3009 mL	0.6018 mL	1.5046 mL
	60 mM	0.0502 mL	0.2508 mL	0.5015 mL	1.2538 mL
	80 mM	0.0376 mL	0.1881 mL	0.3762 mL	0.9404 mL
	100 mM	0.0301 mL	0.1505 mL	0.3009 mL	0.7523 mL

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Zanamivir139110-80-8扎那米韦Influenza VirusAntibioticInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Zanamivir (Synonyms: 扎那米韦)

Customer Review

Other Forms of Zanamivir:

MCE 顾客使用本产品发表的 14 篇科研文献

Zanamivir 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Antibiotic 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Zanamivir 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Zanamivir (Synonyms: 扎那米韦)

Customer Review

Other Forms of Zanamivir:

Zanamivir 相关抗体

MCE 顾客使用本产品发表的 14 篇科研文献

Zanamivir 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Antibiotic 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Zanamivir 相关抗体:

摩尔计算器

稀释计算器

Zanamivir 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z